FDA Relies On Experience To Judge Firazyr Self-Administration
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Center for Devices and Radiological Health recommended a delay in approving Firazyr until a human factors study could be conducted to rule out risks associated with the self-administration device, but CDER reviewers concluded that experience with the device in clinical trials and real life was sufficient to demonstrate safety.